Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the ...

Substitution monotherapy and add-on therapy were equally effective as a second-line treatment for women with idiopathic generalized epilepsy, with no significant differences in failure rates between ...

-- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to submit NAUTILUS PMA Supplement to ...

NeuroPace, Inc. NPCE is tightening its focus on the core RNS franchise as it exits the DIXI distribution and leans into ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

G400 Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset G4000 Localization-related (focal) (partial) idiopathic epilepsy and epileptic ...